^
Association details:
Biomarker:MUC16 mutation
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors

Published date:
08/03/2020
Excerpt:
Both NSCLC and melanoma cohorts included ICI-treated patients…MUC16 mutation was associated with improved overall survival in both the NSCLC (hazard ratio, 0.34; 95% CI, 0.12-0.99; P = .04) and melanoma (hazard ratio, 0.57; 95% CI, 0.36-0.90; P = .02) cohorts.
DOI:
10.1001/jamanetworkopen.2020.13201